Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CING NASDAQ:LSTA NYSEAMERICAN:OGEN NASDAQ:SNYR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCINGCingulate$4.11-5.5%$4.05$3.02▼$6.01$22.24M-0.75144,935 shs174,952 shsLSTALisata Therapeutics$2.37-2.5%$2.44$1.87▼$4.20$20.76M1.0432,018 shs14,944 shsOGENOragenics$1.30-6.5%$1.21$1.01▼$18.90$5.37M0.83303,276 shs165,475 shsSNYRSynergy CHC$2.23-4.3%$2.71$1.30▼$10.00$21.06MN/A404,693 shs40,072 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCINGCingulate+3.33%+7.14%+12.69%0.00%+0.23%LSTALisata Therapeutics-3.95%-4.71%+10.45%-10.33%-20.59%OGENOragenics0.00%+2.96%+19.31%-2.11%-87.90%SNYRSynergy CHC-3.72%-6.05%+4.02%-25.08%-42.47%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCINGCingulate$4.11-5.5%$4.05$3.02▼$6.01$22.24M-0.75144,935 shs174,952 shsLSTALisata Therapeutics$2.37-2.5%$2.44$1.87▼$4.20$20.76M1.0432,018 shs14,944 shsOGENOragenics$1.30-6.5%$1.21$1.01▼$18.90$5.37M0.83303,276 shs165,475 shsSNYRSynergy CHC$2.23-4.3%$2.71$1.30▼$10.00$21.06MN/A404,693 shs40,072 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCINGCingulate+3.33%+7.14%+12.69%0.00%+0.23%LSTALisata Therapeutics-3.95%-4.71%+10.45%-10.33%-20.59%OGENOragenics0.00%+2.96%+19.31%-2.11%-87.90%SNYRSynergy CHC-3.72%-6.05%+4.02%-25.08%-42.47%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCINGCingulate 2.67Moderate Buy$26.25538.69% UpsideLSTALisata Therapeutics 2.33Hold$23.50891.56% UpsideOGENOragenics 0.00N/AN/AN/ASNYRSynergy CHC 3.00Buy$10.00348.43% UpsideCurrent Analyst Ratings BreakdownLatest OGEN, SNYR, CING, and LSTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025CINGCingulateWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025LSTALisata TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SNYRSynergy CHCWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/27/2025CINGCingulateWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025LSTALisata TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SNYRSynergy CHCWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)8/22/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$61.00 ➝ $62.008/21/2025LSTALisata TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.008/8/2025CINGCingulateRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/15/2025LSTALisata TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $32.00(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCINGCingulateN/AN/AN/AN/A$2.32 per shareN/ALSTALisata Therapeutics$1M20.76N/AN/A$3.49 per share0.68OGENOragenics$40K134.23N/AN/A($0.51) per share-2.55SNYRSynergy CHC$33.70M0.62$0.25 per share9.10($1.91) per share-1.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCINGCingulate-$15.55M-$4.10N/AN/AN/AN/A-232.16%-132.07%11/6/2025 (Estimated)LSTALisata Therapeutics-$19.99M-$2.23N/AN/AN/AN/A-69.68%-59.44%11/11/2025 (Estimated)OGENOragenics-$10.57M-$21.42N/A∞N/AN/A-3,614.27%-324.80%N/ASNYRSynergy CHC$2.12M$0.385.873.78N/A10.02%-18.56%20.28%N/ALatest OGEN, SNYR, CING, and LSTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025CINGCingulate-$0.82N/AN/AN/AN/AN/A8/19/2025Q2 2025CINGCingulate-$0.82-$1.09-$0.27-$1.09N/AN/A8/14/2025Q2 2025SNYRSynergy CHC$0.08$0.17+$0.09$0.17$10.80 million$6.74 million8/7/2025Q2 2025LSTALisata Therapeutics-$0.65-$0.54+$0.11-$0.54N/A$0.07 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCINGCingulateN/AN/AN/AN/AN/ALSTALisata TherapeuticsN/AN/AN/AN/AN/AOGENOragenicsN/AN/AN/AN/AN/ASNYRSynergy CHCN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCINGCingulateN/A1.521.52LSTALisata TherapeuticsN/A5.775.77OGENOragenicsN/A0.500.50SNYRSynergy CHCN/A2.742.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCINGCingulate41.31%LSTALisata Therapeutics8.94%OGENOragenics18.71%SNYRSynergy CHCN/AInsider OwnershipCompanyInsider OwnershipCINGCingulate4.04%LSTALisata Therapeutics9.60%OGENOragenics4.90%SNYRSynergy CHC56.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCINGCingulate205.41 million5.19 millionNot OptionableLSTALisata Therapeutics308.76 million7.92 millionNot OptionableOGENOragenics54.13 million3.93 millionN/ASNYRSynergy CHC409.44 million4.10 millionN/AOGEN, SNYR, CING, and LSTA HeadlinesRecent News About These CompaniesSynergy CHC (NASDAQ:SNYR) Given Hold (C-) Rating at Weiss RatingsOctober 9 at 2:13 AM | americanbankingnews.comAt US$2.50, Is Synergy CHC Corp. (NASDAQ:SNYR) Worth Looking At Closely?October 2, 2025 | finance.yahoo.comMAGA Stocks Undercard: SNYR GUTS MRM MYSE Under $3 To Watch Now….more insideSeptember 27, 2025 | theglobeandmail.comSynergy CHC appoints Scott Woodburn as head, strategic partnershipsSeptember 22, 2025 | msn.comSynergy CHC Announces Leadership Changes to Boost GrowthSeptember 22, 2025 | msn.comSynergy CHC (NASDAQ: SNYR) Taps Former Coca-Cola Executive to Lead Strategic Partnerships; Appoints Veteran Costco Buyer to Board of DirectorsSeptember 22, 2025 | markets.businessinsider.comSynergy CHC partners with AlaBev to launch FOCUSfactor beveragesSeptember 17, 2025 | msn.comSynergy CHC Corp. Partners with AlaBev to Extend Distribution of FOCUSfactor® Products in AlabamaSeptember 17, 2025 | quiverquant.comQSynergy CHC Corp. (NASDAQ: SNYR) Partners with AlaBev to Launch FOCUSfactor® Beverages in 5,000+ Retail Outlets Across AlabamaSeptember 17, 2025 | globenewswire.comSynergy CHC Completes $4.375M Public OfferingAugust 27, 2025 | tipranks.comSynergy CHC Corp. Announces the Closing of its $4.375 Million Public OfferingAugust 27, 2025 | globenewswire.comSynergy CHC 1.75M share Secondary priced at $2.50August 26, 2025 | msn.comSynergy CHC Corp. Announces Pricing of $4.375 Million Public Offering | SNYR Stock NewsAugust 25, 2025 | gurufocus.comSynergy CHC Corp. Announces Pricing of $4.375 Million Public Offering of Common StockAugust 25, 2025 | quiverquant.comQSynergy CHC Corp. Announces Pricing of $4.375 Million Public OfferingAugust 25, 2025 | globenewswire.comSynergy CHC's (NASDAQ:SNYR) Earnings Quality Is LowAugust 22, 2025 | finance.yahoo.comSynergy CHC Corp to Present at the 2025 Gateway Conference on September 4thAugust 21, 2025 | markets.businessinsider.comNew to The Street’s Esteemed Client Synergy CHC Corp. (NASDAQ: SNYR) Announces Nationwide EG America Rollout for FOCUSfactor(R) Focus + Energy EG America, 6th Largest U.S ...August 20, 2025 | palmbeachpost.comPSynergy CHC Corp. (NASDAQ: SNYR) Announces Nationwide EG America Rollout for FOCUSfactor® Focus + EnergyAugust 18, 2025 | taiwannews.com.twTNew to The Street's Esteemed Client Synergy CHC Corp. Announces Nationwide EG America Rollout for FOCUSfactor Focus + Energy EG America, 6th Largest U.S. Convenience Chain ...August 18, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAfter the Fed's Rate Cut, PNC Could See a Mortgage Refinance BoomBy Jordan Chussler | September 21, 2025Carmax: Now is the Time to Load Up On This Used Car StockBy Thomas Hughes | September 26, 2025Rocket Lab’s Bullish Case Remains Intact Despite Recent OfferingBy Ryan Hasson | September 24, 2025McDonald’s: New All-Time Highs Are InevitableBy Thomas Hughes | September 19, 2025Why Affirm Could Be the Next Big Winner in Rate-Cut RallyBy Gabriel Osorio-Mazilli | September 26, 2025OGEN, SNYR, CING, and LSTA Company DescriptionsCingulate NASDAQ:CING$4.11 -0.24 (-5.52%) Closing price 04:00 PM EasternExtended Trading$3.96 -0.15 (-3.65%) As of 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Lisata Therapeutics NASDAQ:LSTA$2.37 -0.06 (-2.47%) Closing price 04:00 PM EasternExtended Trading$2.40 +0.02 (+1.05%) As of 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.Oragenics NYSEAMERICAN:OGEN$1.30 -0.09 (-6.47%) Closing price 04:10 PM EasternExtended Trading$1.29 -0.01 (-0.69%) As of 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.Synergy CHC NASDAQ:SNYR$2.23 -0.10 (-4.29%) As of 03:59 PM EasternSynergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Adobe Launches Premiere Pro on iPhone, Upside Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
